The Organ Protection of Astragalus in Subjects With Metabolic Syndrome

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In this study, prospective randomized, controlled, parallel designed ,different doses of Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time quantitative PCR and Western Blotting to detect the index of oxidative stress 、angiotensin-converting enzyme 2 mRNA expression and proteins.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LanZhou University

Criteria

Inclusion Criteria:

1. age 18 years or older, meet the diagnostic criteria of MS

2. non-allergic with the astragalus

3. agree to conduct clinical trials and those who signed the informed consent

Exclusion Criteria:

1. patients with resistant hypertension

2. renal disease requiring dialysis

3. heart failure NYHA ⅢorⅣ;

4. complications of diabetes

5. arteritis

6. cancer

7. thyroid disease

8. unstable coronary heart disease

9. peripheral vascular disease

10. acute cerebral vascular disease11.pregnancy、 planned pregnancy

11. patients with anti-oxidants

12. acute infection

13. other organic dysfunction, such as the liver, respiratory system, blood system, and other rheumatic diseases.